SEC Form 4 · accession 0001140361-17-034453
IDEXX LABORATORIES INC /DE · IDXX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stuart Essig
Director
Period of report
Sep 1, 2017
Accepted (ET)
Sep 6, 2017 · 6:04 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000874716
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Stock UnitF1,F4,F2 | — | Sep 1, 2017 | A | 240 | A | — | — | Common Stock | 240 | 240 | D |
| Non-Qualified Stock Option (right-to-buy)F1,F4,F3 | $154.98 | Sep 1, 2017 | A | 2,532 | A | — | Aug 31, 2027 | Common Stock | 2,532 | 2,532 | D |
Explanation of responses
- F1This equity grant represents pro rata equity compensation earned by the reporting person as a non-employee Director from his election to the IDEXX Laboratories, Inc. Board of Directors on July 12, 2017 until the 2018 annual meeting of stockholders.
- F2Each deferred stock unit ('DSU') represents a contingent right to receive one share of IDEXX Laboratories, Inc. common stock. These DSUs will fully vest on the date of the 2018 annual meeting of stockholders or May 3, 2018, whichever event occurs earlier, and are payable as common stock one year following the Director's resignation from the Board of Directors.
- F3Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that vests in one installment on May 3, 2018.
- F4Not applicable.